期刊文献+

5′-NT及其与ALT联合检测在鉴别ALP升高的恶性肿瘤骨转移中的价值 被引量:3

The value of serum 5′-nucleotidase and its combination with alanine aminotransferase in identifying bone metastases in cancer patients with elevated ALP
下载PDF
导出
摘要 目的研究血清5′核苷酸酶(5′-NT)及其与丙氨酸氨基转移酶(ALT)联合检测在鉴别血清碱性磷酸酶(ALP)升高的恶性肿瘤骨转移中的价值。方法选取2018年12月~2019年8月中国医学科学院北京协和医学院肿瘤医院就诊恶性肿瘤患者176例。其中血清ALP水平升高但无骨转移患者88例为ALP升高肝癌组;血清ALP水平升高但其余肝功能指标均正常的骨转移患者88例为ALP升高恶性肿瘤骨转移组;同期选取健康志愿者50名为正常对照组。测定三组血清5′-NT及ALT水平。结果 ALP升高肝癌组5′-NT阳性率高于ALP升高恶性肿瘤骨转移组(P <0.01),ALP升高肝癌组血清5′-NT水平高于ALP升高恶性肿瘤骨转移组及正常对照组(P <0.01)。血清5′-NT或ALT水平升高为ALP升高恶性肿瘤患者骨转移的保护因素。5′-NT判断ALP升高为恶性肿瘤骨转移的曲线下面积(AUC)为0.966,当临界值<5.6 U/L,灵敏度为90.91%,特异性为89.77%;5′-NT联合ALT检测时AUC为0.980,特异度可提高至96.49%。结论 5′-NT及ALT联合检测在鉴别ALP升高的恶性肿瘤骨转移中具有一定的临床价值。 Objective To explore the value of serum 5′-nucleotidase(5′-NT)and its combination with alanine aminotransferase(ALT)in identifying bone metastases in cancer patients with elevated alkaline phosphatase(ALP).Methods A total of 176 cancer patients who enrolled from Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College from December 2018 to August 2019 were selected.Among them,88 cases with elevated ALP but without bone metastasis were named the liver cancer with elevated ALP group;other 88 cases with bone metastasis and elevated ALP but normal liver function were named the cancer with bone metastasis and elevated ALP group;50 healthy volunteers were named the normal control group at the same time.The levels of serum 5′-NT and ALT were detected in three groups.Results The positive rate of 5′-NT in the liver cancer with elevated ALP group was higher than that in the cancer with bone metastasis and elevated ALP group(P<0.01).The serum levels of 5′-NT in liver cancer with elevated ALP group were higher than those in the cancer with bone metastasis and elevated ALP group and the normal control group(P<0.01).The increased serum 5′-NT or ALT levels were protective factors for bone metastases in cancer patients with elevated ALP.The area under the curve(AUC)of 5′-NT to judge the elevation of ALP to malignant tumor bone metastasis was 0.966,and the sensitivity was 90.91%and the specificity was 89.77%when the critical value was<5.6 U/L.The AUC of 5′-NT combined with ALT was 0.980,and the specificity was increased to96.49%.Conclusion The combined detection of 5′-NT and ALT has a certain clinical value in differentiating bone metastases of malignant tumors with elevated ALP.
作者 崔婵娟 高佳 李佳 于梦瑶 张浩 崔巍 CUI Chanjuan;GAO Jia;LI Jia;YU Mengyao;ZHANG Hao;CUI Wei(Department of Laboratory Medicine,National Cancer Center National Clinical Research Center for Cancer Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
机构地区 国家癌症中心
出处 《中国医药导报》 CAS 2020年第17期109-112,共4页 China Medical Herald
基金 国家自然科学基金面上项目(81772272) 中国医学科学院医学与健康科技创新工程(2017-I2M-3-005)。
关键词 5′核苷酸酶 碱性磷酸酶 肿瘤 骨转移 5′-nucleotidase Alkaline phosphates Cancer Bone metastases
  • 相关文献

参考文献3

二级参考文献46

  • 1卞莹,郑玲.骨代谢生化指标在诊治恶性肿瘤骨转移中的临床价值[J].现代临床医学,2009,35(2):89-91. 被引量:6
  • 2范义湘,罗荣城,李贵平,黄凯.骨显像联合血清骨型碱性磷酸酶诊断恶性肿瘤骨转移[J].第一军医大学学报,2004,24(7):812-814. 被引量:7
  • 3余靖,邸立军,宛凤玲,勇威本.骨代谢生化指标和恶性肿瘤骨转移不同临床表现的关系[J].肿瘤防治研究,2006,33(5):364-367. 被引量:9
  • 4Kiuchi K, Ishikawa T, Hamaguchi Y, et al. Cross-linked collagen C- and N telopeptides for an early diagnosis of bone metastasis from breast cancer. Oncol Rep, 2002, 9(3): 595-598.
  • 5Walls J, Assiri A, Howell A, et al. Measurement of urinary collagen crosslinks indicate response to therapy in patients with breast cancer and bone metastases. Br J Cancer 1999, 80(8): 1265-1270.
  • 6Horiguchi T, Tachikawa S, Kordo R, et al. Usefulness of type I collagen (ICTP) as a marker of bone metastasis from lung cancer. Jpn J Clin Oncol, 2000, 30(4): 174-179.
  • 7Nakamura H, Oishi S, Yagyu H, et al. Comparative study of bone resorption markers for the diagnosis of bone metastasis in lung cancer. Nihon Kokyuki Gakkai Zasshi, 2002, 40(5): 355-359.
  • 8Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.J Clinl Oncol, 2002, 20(3): 850-856.
  • 9Martinetti A, Ripamonti C, Miceli R, et al. Short-term effects ofpamidronate on bone turnover: Can bone markers be considered predictive of the analgesic response? Oncol Rep, 2007, 17(6): 1533-1540.
  • 10Harmon RA, Eastell R. Bone markers and current laboratory assays. Cancer Treatment Rev, 2006, 32 (Suppl): 7-14.

共引文献50

同被引文献39

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部